Latest News and Press Releases
Want to stay updated on the latest news?
-
BETHLEHEM, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome...
-
Q3 GAAP EPS of $0.15; Q3 Non-GAAP EPS of $0.27 Grew cash balance to $224.9 million as of September 30, 2023 BETHLEHEM, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:...
-
BETHLEHEM, Pa., Oct. 23, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2023 financial results and...
-
InteliSwab® test revenue of $47.5 million in Q2 Q2 Core revenue of $37.9 million grew 4% sequentially and 3% year-over-year Q2 GAAP EPS of $(0.07); Q2 Non-GAAP EPS of $0.09 Grew cash...
-
BETHLEHEM, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2023 second quarter financial results and...
-
BETHLEHEM, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome...
-
BETHLEHEM, Pa., June 13, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and at-home diagnostic testing, as well as non-invasive self-sampling...
-
InteliSwab® test revenue of $118.3 million in Q1, up 33% sequentially; Company delivers cost savings and begins to taper InteliSwab® test production and expenses Gross margins increase 200 basis...
-
BETHLEHEM, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2023 first quarter financial results and...
-
InteliSwab® revenue of $88.9 million in Q4, up 12% sequentially; wins two new federal government contracts extending the tail on InteliSwab® revenue Signs a deal with Quest Diagnostics Genomic...